

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

| F. | | ş | www.uspto.gov | |
|--|---------------|--|-------------------------|------------------|
| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
| 09/545,659 | 04/10/2000 | Rong-hao Li | 415072000600 | 2403 |
| 25226 75 | 90 07/17/2002 | \ \ \ \ | | |
| MORRISON & FOERSTER LLP | | | EXAMINER | |
| 755 PAGE MILL RD PALO ALTO, CA 94304-1018 | | `` ! | LANKFORD JR, LEON B | |
| 11 - براجع | | \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ | ART UNIT | PAPER NUMBER |
| <u>1</u> : | | | 1651 | |
| | | | DATE MAILED: 07/17/2002 | 15 |

Please find below and/or attached an Office communication concerning this application or proceeding.

| | Application No. | Applicant(s) | | | | |
|---|-------------------------|--|--|--|--|--|
| | 09/545,659 | LI ET AL. | | | | |
| Office Action Summary | Examiner | Art Unit | | | | |
| | L Blaine Lankford | 1651 | | | | |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply | | | | | | |
| • • | | | | | | |
| A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). | | | | | | |
| Status | | | | | | |
| 1) Responsive to communication(s) filed on 19 April 2002. | | | | | | |
| 2a) This action is FINAL . 2b) ⊠ Thi | s action is non-final. | | | | | |
| 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims | | | | | | |
| 4)⊠ Claim(s) <u>1-14</u> is/are pending in the application | | | | | | |
| 4a) Of the above claim(s) 8-11 and 14 is/are withdrawn from consideration. | | | | | | |
| 5) Claim(s) is/are allowed. | | | | | | |
| 6)⊠ Claim(s) <u>1-7,12 and 13</u> is/are rejected. | | | | | | |
| 7) Claim(s) is/are objected to. | | | | | | |
| 8) Claim(s) are subject to restriction and/or election requirement. | | | | | | |
| Application Papers | | | | | | |
| 9)☐ The specification is objected to by the Examiner. | | | | | | |
| 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. | | | | | | |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). | | | | | | |
| 11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner. | | | | | | |
| If approved, corrected drawings are required in reply to this Office action. | | | | | | |
| 12)☐ The oath or declaration is objected to by the Examiner. | | | | | | |
| Priority under 35 U.S.C. §§ 119 and 120 | | | | | | |
| 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). | | | | | | |
| a) ☐ All b) ☐ Some * c) ☐ None of: | | | | | | |
| 1. Certified copies of the priority documents have been received. | | | | | | |
| 2. Certified copies of the priority documents have been received in Application No | | | | | | |
| Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the etterhood detailed Office action for a list of the partified copies not received. | | | | | | |
| * See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). | | | | | | |
| a) The translation of the foreign language provisional application has been received. | | | | | | |
| 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. | | | | | | |
| Attachment(s) | 4) D Javanijani 0 | (DTO 442) Dance No (c) | | | | |
| Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s) | 5) Notice of Informal F | (PTO-413) Paper No(s) Patent Application (PTO-152) | | | | |
| | | | | | | |

2.

Application/Control Number: 09/545,659

Art Unit: 1651

DETAILED ACTION

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 1-7 are rejected under 35 U.S.C. 102(b) as being anticipated by van Niekerk et al (Int J Cancer 43, 1989) or Zeihmet et al (Gynecologic Oncology 62, 1996).

Zeihmet and van Niekerk teach isolated cultures of ovarian mesothelial cells.

The references don't teach all of applicant's claimed characteristics however such markers, etc would be inherent to the cells as the cells populations are identical. The references do teach that the cells have the cell markers cytokeratin and vimentib. The references anticipate the claim subject matter.

Claims 12 & 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over van Niekerk et al (Int J Cancer 43, 1989) or Zeihmet et al (Gynecologic Oncology 62, 1996).

The teachings of the two references are set forth above. The references do not specifically teach using the cells in an assay or isolating cellular products/components from the cells and using them in assays, etc. However, it would have been obvious at the time the invention was made to use the cells of the two references in assays determining the effects of substances on said cells or to isolate and use the cellular

Art Unit: 1651

products of the cells because these are obvious uses and utilities of isolated cells/cell lines. These methods are notoriously old and well known applications of cells.

Accordingly, the claimed invention was prima facie obvious to one of ordinary skill in the art at the time the invention was made especially in the absence of evidence to the contrary.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to L Blaine Lankford whose telephone number is 308-2455. The examiner can normally be reached on Mon-Thu 7:30-6.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Wityshyn can be reached on 308-4743. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 308-0196.

L Blaine Lankford Primary Examiner Art Unit 1651

LBL July 15, 2002